79794-75-5

Basic information

• Product Name: Loratadine
• Synonyms: LORATADINE;LORATADINE-D5;LORATIDINE;CLARATYNE;CLARITIN;ethyl 4-(8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate;4(8-CHLORO-5,6-DIHYDRO-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLATE;4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLIC ACID ETHYL ESTER
• CAS NO: 79794-75-5
• Molecular Formula: C₂₂H₂₃ClN₂O₂
• Molecular Weight: 382.88
• EINECS: 1308068-626-2
• Product Categories: Active Pharmaceutical Ingredients;Intermediates & Fine Chemicals;Pharmaceuticals;API's;Histamine receptor;Amines;Heterocycles;Pharmaceutical intermediate;Other APIs
• Mol File: 79794-75-5.mol
• Article Data: 28

Chemical Properties

• Melting Point: 134-136°C
• Boiling Point: 531.3 ºC at 760 mmHg
• Flash Point: 275.1 ºC
• Appearance: white/powder
• Density: 1.261 g/cm³
• Storage Temp.: 2-8°C
• Solubility: DMSO: 26 mg/mL, soluble
• PKA: 4.27±0.20(Predicted)
• Water Solubility: It is soluble in DMSO (50 mg/ml), ethanol (77 mg/ml at 25°C), water (<1 mg/ml at 25°C), chloroform, and methanol.
• Stability: Stable, but may be heat sensitive - refrigerate. Incompatible with strong oxidizing agents.
• Merck: 14,5578
• CAS DataBase Reference: Loratadine(CAS DataBase Reference)
• NIST Chemistry Reference: Loratadine(79794-75-5)
• EPA Substance Registry System: Loratadine(79794-75-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 22-24/25-36-26
• RIDADR: 3077
• WGK Germany: 2
• RTECS: TM6129200
• Hazardous Substances Data: 79794-75-5(Hazardous Substances Data)

Usage

Abstract

Loratadine, sold under the brand name Claritin among others.Loratadine(Claritin) is a long-acting, non-sedating antihistamine that is used for the treatment of allergies. Histamine is a chemical that causes many of the signs and symptoms of an allergy. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine on their surfaces. Histamine stimulates the cells to release chemicals that produce effects that we associate with allergy, including welts, itching, and tissue swelling. Loratadine(Claritin) blocks one type of histamine receptor (the H1 receptor) and thus prevents activation of cells with H1 receptors by histamine.

Antiallergic

Loratadine is a common antiallergic medication, which is a second generation long-acting tricyclic antihistamine, rapid onset of action is strong, does not contain hormones, absorbed by the body metabolism with more active desloratadine, inhibiting histamine H1 receptor by competitively inhibit histamine-induced allergic symptoms, with? no obvious anticholinergic and central inhibition. It is used for the relief of clinical symptoms of allergic rhinitis related, such as sneezing, runny nose and nasal itching, eye itching and burning. It is also used to relieve symptoms of chronic urticaria and other allergic skin diseases.

Drug Interactions

Inhibition of hepatic drug-metabolizing enzyme function drugs can slow the metabolism of the product, such as itraconazole, ketoconazole, Daily with 400 mg ketoconazole suit, can make the product and its active metabolite to carboxyethyl loratadine increased plasma concentrations, but it was not observed in the changes of electrocardiogram (ECG). It can also inhibit the metabolism of loratadine when used with macrolides, cimetidine, theophylline and other drugs together.

Application

Antihistamines, peripheral nerves are highly selective H1-receptor, the role of strong, long time. For allergic arthritis, allergic rhinitis. National second-class anti-allergy drugs, for the relief of seasonal allergic rhinitis nasal and non-nasal symptoms and relieve chronic urticaria.

Side effects

Common side effects include sleepiness, dry mouth, and headache. Serious side effects are rare and include allergic reactions, seizures, and liver problems. Use during pregnancy appears to be safe but has not been well studied. It is not recommended in children less than two years old. It is in the second-generation antihistamine family of medication.

Preparation

Compound (I) (0.05mo1) was dissolved in toluene (450m1), dropwise addition of ethyl chloroformate (0.15mo1). Canada finished in the sauna heating 2h, and then stirred at room temperature overnight. Added 800ml water. The benzene layer was separated, washed with water, and dried. Decompression concentrated oil, with petroleum ether after impregnation with acetonitrile, recrystallization, the yield of loratadine, 64%.

References

https://en.wikipedia.org/wiki/Loratadine http://www.medicinenet.com/loratadine/article.htm

Description

Loratadine is a non-sedating antihistamine indicated for use in allergic rhinitis and chronic urticaria. Its major advantage over other non-sedating antihistamines such as astemizole and terfenadine is its very fast onset of action. Loratadine is claimed not to cross the blood-brain barrier.

Chemical Properties

White Crystalline Solid

Uses

Different sources of media describe the Uses of 79794-75-5 differently. You can refer to the following data:
1. antinflammatory, analgesic, antipyretic
2. A nonsedating-type histamine H1-receptor
3. Loratadine, is used as a peripheral histamine H1 receptor agonist. It is also used as an orally active antiallergic agent. It is an important raw material and intermediate used in Organic Synthesis, Pharmaceuticals, Agrochemicals and Dyestuff.

Indications

Loratadine (Claritin) is a long-acting, potent peripheral H1 blocker with minimal sedative effects. It does not appear to have the same adverse cardiac effects as the other nonsedating H1 antihistamines. It is indicated for allergic rhinitis and chronic urticaria.

Manufacturing Process

Preparation of Loratadine In a two-liter vessel provided with a thermometer, a reflux condenser and nitrogen atmosphere, dry tetrahydrofuran (343 ml) was placed, and cooled between 0 and -5°C. Titanium tetrachloride (28.5 ml, 49.5 g, 0.255 mol) was slowly added with stirring (17 min.), keeping the temperature in the above indicated range, a yellow suspension being formed. After the addition was finished, stirring was continued for 10 min. Then, zinc dust (34.5 g, 0.524 mol) was added with stirring in approximately 15 min. keeping the temperature in the above cited range, and after addition was finished, stirring was continued at this temperature for 20 min., a blue suspension being formed. Then, pyridine (17 ml, 0.21 mol) was added with stirring, keeping the temperature in the above range, and then, a solution of 8-chloro-5,6- dihydrobenzo[5,6]cyclohepta[1,2-b]pyridin-11-one (30.0 g, 0.123 mol) and ethyl 4-oxopiperidine-1-carboxylate (25.2 g, 0.147 mol) in anhydrous tetrahydrofuran (96 ml) was added in about 20 min., with stirring and keeping the temperature in the above cited range. The, thus obtained, dark brown mixture was stirred for 3 h keeping the temperature in the above cited range, then was allowed to heat to room temperature and kept at this temperature for 2 h and then heated to 40°C for 17 h. The tetrahydrofuran was distilled off from the reaction mixture to give a black resin that was dissolved in dichloromethane (300 ml) and acidified by addition of isopropanol/HCl 7.2 N (97 ml). The mixture was stirred for 10 min, and the phases were separated, being the aqueous one extracted with dichloromethane (150 ml). The combined organic phases were washed 6 times with a mixture of water (125 ml) and 35% aqueous HCl (7.5 ml). Then, the organic phase was basified to pH 7.5-8.0 by addition of 30% aqueous NH3. The mixture was stirred for 10 min and the phases were separated, and then washed 3 times with water (250 ml). The organic phase was dried with anhydrous sodium sulfate, filtered and the solvent eliminated in vacuo to give a residue (47.47 g) that was treated with acetonitrile (97 ml). The solid was filtered and crystallized from the same solvent to give pure Loratadine, m.p. 132-133°C (18.8 g, 40% yield).

Brand name

Alavert (Wyeth); Claritin (Schering-Plough).

General Description

Loratadine, 4-(8-chloro-5,6-dihydro-11Hbenzo[5,6]-cyclohepta[1,2-b]pyridin-l 1-ylidene-1-carboxylic acid ethyl ester, is a white to off-white powder insoluble in water but very soluble in acetone, alcohols, and chloroform. Loratadine is structurally related to the antihistamines azatadine and cyproheptadine, and to some tricyclic antidepressants. It differs from azatadine, in that a neutral carbamate group has replaced the basic tertiary amino moiety, and a phenyl ring has been substituted with a chlorine atom. Loratadine is a selective peripheral H1-antihistamine with a receptor-binding profile like that of the other members of this series, except that it has more antiserotonergic activity. Thus, it produces no substantial CNS or autonomic side effects or cardiac toxicity. Loratadine displays potency comparable with that of astemizole and greater than that of terfenadine. Loratadine is indicated for the relief of nasal and nonnasal symptoms of seasonal allergic rhinitis. In the presence of a CYP3A4 inhibitor ketoconazole, loratadine is metabolized to descarboethoxyloratadine predominantly by CYP2D6.

Biological Activity

Peripheral histamine H 1 receptor antagonist (K i = 35 nM); devoid of central effects. Orally active antiallergic agent.

Biochem/physiol Actions

Non-sedating histamine H1-receptor antagonist.

Pharmacokinetics

Good oral absorption, rapid and extensive metabolism in the liver, and excreted by urine and feces. After taking the medicine, the effect is fast, and some patients show the effect within 30 minutes. Tmax is 1.5 ~ 2 h, and the elimination half-life is 8 ~ 14 h. The half-life of the active metabolite decarboxymethylethoxyloratadine (DCL) is 17 ~ 24h. The half-life of the elderly and patients with liver disease may be longer. The binding rate of loratadine to plasma protein was 97% ~ 99%, and DCL was 73% ~ 76%. After 24 hours, about 27% of loratadine was excreted from urine, about 40% was eliminated from urine and 42% was excreted from stool after 10 days. With less milk secretion, it is safe to use drugs during lactation.

Clinical Use

Loratadine is related to the first-generation tricyclic antihistamines and to antidepressants. It is nonsedating, and neither it nor its major metabolite, desloratadine (descarboethoxyloratadine), is associated with the potentially cardiotoxic effects reported for terfenadine and astemizole. On chronic dosing, the AUC (plasma concentration–time curve) for the metabolite is greater than that for the parent drug, and its half-life is longer.

Drug interactions

Molecular weight (daltons) 382.9 % Protein binding 97-99 % Excreted unchanged in urine 40 Volume of distribution (L/kg) No data Half-life - normal/ESRF (hrs) 12-15 / Unchanged

Metabolism

Molecular weight (daltons) 382.9 % Protein binding 97-99 % Excreted unchanged in urine 40 Volume of distribution (L/kg) No data Half-life - normal/ESRF (hrs) 12-15 / Unchanged

Dosage forms

10 mg daily. Patients with liver or renal impairment should be started on a lower dose.

InChI:InChI=1/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

Synthetic route

chloroformic acid ethyl ester (541-41-3) + N-methyldesloratadine (38092-89-6) → loratadine (79794-75-5)

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In toluene at 60 - 75℃; for 1 - 2h;	90%
Stage #1: chloroformic acid ethyl ester; N-methyldesloratadine With N-ethyl-N,N-diisopropylamine In toluene at 60 - 75℃; for 1 - 2h; Stage #2: With hydrogenchloride In water; toluene	73%
With triethylamine In toluene for 3h; Reflux;	72%

diethyl N-ethoxycarbonylpiperidine-4-phosphonate (216870-24-5) → loratadine (79794-75-5)

Conditions	Yield
With hydrogenchloride In N,N-dimethyl acetamide; isopropyl alcohol at 20 - 140℃; under 760.051 Torr; for 2h;	82%

2-cyano-3-methylpyridine (20970-75-6) → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 7 steps 1: 97 percent / conc. H2SO4 / 0.5 h / 75 °C 2: 1.) n-BuLi, NaBr / 1.) THF, hexane, -40 deg C, 10 min, 2.) THF, hexane, -40 deg C, 30 min 3: 1.) POCl3, 2.) 50percent aq. NaOH / 1.) reflux, 3 h, 2.) 30 deg C, 2 h, pH 8 4: tetrahydrofuran / 0.5 h / 40 - 50 °C 5: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 6: 20 g / BF3 / 4 h / 120 °C 7: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 7 steps 1: 97 percent / conc. H2SO4 / 0.5 h / 75 °C 2: 1.) n-BuLi, NaBr / 1.) THF, hexane, -40 deg C, 10 min, 2.) THF, hexane, -40 deg C, 30 min 3: 1.) POCl3, 2.) 50percent aq. NaOH / 1.) reflux, 3 h, 2.) 30 deg C, 2 h, pH 8 4: tetrahydrofuran / 0.5 h / 40 - 50 °C 5: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 6: 91 percent / hydrofluoric acid, BF3 / -35 °C 7: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 7 steps 1: 97 percent / conc. H2SO4 / 0.5 h / 75 °C 2: 1.) n-BuLi, NaBr / 1.) THF, hexane, -40 deg C, 10 min, 2.) THF, hexane, -40 deg C, 30 min 3: 1.) POCl3, 2.) 50percent aq. NaOH / 1.) reflux, 3 h, 2.) 30 deg C, 2 h, pH 8 4: tetrahydrofuran / 0.5 h / 40 - 50 °C 5: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 6: 44 percent / polyphosphoric acid (PPA) / 8 h / 190 °C 7: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 6 steps 1.1: sulfuric acid / 0.5 h / 70 - 75 °C 2.1: n-butyllithium / tetrahydrofuran / 0.33 h / -30 - -10 °C / Inert atmosphere 2.2: 1 h / -10 °C / Inert atmosphere 3.1: trichlorophosphate / 4 h / 110 °C 4.1: magnesium; iodine / tetrahydrofuran; ethylene dibromide / 1 h / 75 °C / Inert atmosphere 4.2: 1 h / 40 - 50 °C / Inert atmosphere 4.3: 1 h / 20 °C / pH < 2 / Inert atmosphere 5.1: boric acid; sulfuric acid / chlorobenzene / 30 h / 80 - 90 °C 6.1: triethylamine / toluene / 2 h / 80 - 85 °C View Scheme

N-tert-butyl-3-methylpyridine-2-carboxamide (32998-95-1) → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 6 steps 1: 1.) n-BuLi, NaBr / 1.) THF, hexane, -40 deg C, 10 min, 2.) THF, hexane, -40 deg C, 30 min 2: 1.) POCl3, 2.) 50percent aq. NaOH / 1.) reflux, 3 h, 2.) 30 deg C, 2 h, pH 8 3: tetrahydrofuran / 0.5 h / 40 - 50 °C 4: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 5: 20 g / BF3 / 4 h / 120 °C 6: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 6 steps 1: 1.) n-BuLi, NaBr / 1.) THF, hexane, -40 deg C, 10 min, 2.) THF, hexane, -40 deg C, 30 min 2: 1.) POCl3, 2.) 50percent aq. NaOH / 1.) reflux, 3 h, 2.) 30 deg C, 2 h, pH 8 3: tetrahydrofuran / 0.5 h / 40 - 50 °C 4: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 5: 91 percent / hydrofluoric acid, BF3 / -35 °C 6: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 6 steps 1: 1.) n-BuLi, NaBr / 1.) THF, hexane, -40 deg C, 10 min, 2.) THF, hexane, -40 deg C, 30 min 2: 1.) POCl3, 2.) 50percent aq. NaOH / 1.) reflux, 3 h, 2.) 30 deg C, 2 h, pH 8 3: tetrahydrofuran / 0.5 h / 40 - 50 °C 4: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 5: 44 percent / polyphosphoric acid (PPA) / 8 h / 190 °C 6: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 5 steps 1: 1.) n-BuLi / 1.) THF, -40 deg C 2: POCl3 / Heating 3: 2.) aq. HCl / 1.) THF, reflux 4: CF3SO3H / Heating 5: Et3N / toluene / Heating View Scheme
Multi-step reaction with 5 steps 1.1: n-butyllithium / tetrahydrofuran / 0.33 h / -30 - -10 °C / Inert atmosphere 1.2: 1 h / -10 °C / Inert atmosphere 2.1: trichlorophosphate / 4 h / 110 °C 3.1: magnesium; iodine / tetrahydrofuran; ethylene dibromide / 1 h / 75 °C / Inert atmosphere 3.2: 1 h / 40 - 50 °C / Inert atmosphere 3.3: 1 h / 20 °C / pH < 2 / Inert atmosphere 4.1: boric acid; sulfuric acid / chlorobenzene / 30 h / 80 - 90 °C 5.1: triethylamine / toluene / 2 h / 80 - 85 °C View Scheme

3-[2-(3-chlorophenyl)ethyl]-2-pyridine-carbonitrile (31255-57-9) → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 4 steps 1: tetrahydrofuran / 0.5 h / 40 - 50 °C 2: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 3: 20 g / BF3 / 4 h / 120 °C 4: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 4 steps 1: tetrahydrofuran / 0.5 h / 40 - 50 °C 2: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 3: 91 percent / hydrofluoric acid, BF3 / -35 °C 4: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 4 steps 1: tetrahydrofuran / 0.5 h / 40 - 50 °C 2: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 3: 44 percent / polyphosphoric acid (PPA) / 8 h / 190 °C 4: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 3 steps 1: 2.) aq. HCl / 1.) THF, reflux 2: CF3SO3H / Heating 3: Et3N / toluene / Heating View Scheme
Multi-step reaction with 3 steps 1.1: magnesium; iodine / tetrahydrofuran; ethylene dibromide / 1 h / 75 °C / Inert atmosphere 1.2: 1 h / 40 - 50 °C / Inert atmosphere 1.3: 1 h / 20 °C / pH < 2 / Inert atmosphere 2.1: boric acid; sulfuric acid / chlorobenzene / 30 h / 80 - 90 °C 3.1: triethylamine / toluene / 2 h / 80 - 85 °C View Scheme

3-<2-(3-chlorophenyl)ethyl>-N-(1,1-dimethylethyl)-2-pyridinecarboxamide (107285-30-3) → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 5 steps 1: 1.) POCl3, 2.) 50percent aq. NaOH / 1.) reflux, 3 h, 2.) 30 deg C, 2 h, pH 8 2: tetrahydrofuran / 0.5 h / 40 - 50 °C 3: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 4: 20 g / BF3 / 4 h / 120 °C 5: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 5 steps 1: 1.) POCl3, 2.) 50percent aq. NaOH / 1.) reflux, 3 h, 2.) 30 deg C, 2 h, pH 8 2: tetrahydrofuran / 0.5 h / 40 - 50 °C 3: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 4: 91 percent / hydrofluoric acid, BF3 / -35 °C 5: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 5 steps 1: 1.) POCl3, 2.) 50percent aq. NaOH / 1.) reflux, 3 h, 2.) 30 deg C, 2 h, pH 8 2: tetrahydrofuran / 0.5 h / 40 - 50 °C 3: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 4: 44 percent / polyphosphoric acid (PPA) / 8 h / 190 °C 5: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 4 steps 1: POCl3 / Heating 2: 2.) aq. HCl / 1.) THF, reflux 3: CF3SO3H / Heating 4: Et3N / toluene / Heating View Scheme
Multi-step reaction with 4 steps 1.1: trichlorophosphate / 4 h / 110 °C 2.1: magnesium; iodine / tetrahydrofuran; ethylene dibromide / 1 h / 75 °C / Inert atmosphere 2.2: 1 h / 40 - 50 °C / Inert atmosphere 2.3: 1 h / 20 °C / pH < 2 / Inert atmosphere 3.1: boric acid; sulfuric acid / chlorobenzene / 30 h / 80 - 90 °C 4.1: triethylamine / toluene / 2 h / 80 - 85 °C View Scheme

(1-methyl-4-piperidyl)magnesium chloride (63463-36-5) → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 4 steps 1: tetrahydrofuran / 0.5 h / 40 - 50 °C 2: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 3: 20 g / BF3 / 4 h / 120 °C 4: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 4 steps 1: tetrahydrofuran / 0.5 h / 40 - 50 °C 2: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 3: 91 percent / hydrofluoric acid, BF3 / -35 °C 4: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 4 steps 1: tetrahydrofuran / 0.5 h / 40 - 50 °C 2: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 3: 44 percent / polyphosphoric acid (PPA) / 8 h / 190 °C 4: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 3 steps 1: tetrahydrofuran / Reflux 2: sulfuric acid / 4.5 h / 20 °C 3: triethylamine / toluene / 3 h / Reflux View Scheme

C-{3-[2-(3-Chloro-phenyl)-ethyl]-pyridin-2-yl}-C-(1-methyl-piperidin-4-yl)-methyleneamine → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 3 steps 1: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 2: 20 g / BF3 / 4 h / 120 °C 3: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 3 steps 1: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 2: 91 percent / hydrofluoric acid, BF3 / -35 °C 3: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 3 steps 1: 2 N aq. HCl / tetrahydrofuran / 1 h / 25 - 30 °C 2: 44 percent / polyphosphoric acid (PPA) / 8 h / 190 °C 3: 42.4 g / toluene / 1 h / 80 °C View Scheme

1-(METHYL-4-PIPERIDINYL)[3-(2-(3-CHLORO-PHENYL)ETHYL)-2-PYRIDINYL]METHANONE HYDROCHLORIDE (119770-60-4) → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 2 steps 1: 20 g / BF3 / 4 h / 120 °C 2: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 2 steps 1: 91 percent / hydrofluoric acid, BF3 / -35 °C 2: 42.4 g / toluene / 1 h / 80 °C View Scheme
Multi-step reaction with 2 steps 1: 44 percent / polyphosphoric acid (PPA) / 8 h / 190 °C 2: 42.4 g / toluene / 1 h / 80 °C View Scheme

{3-[2-(3-Chloro-phenyl)-ethyl]-pyridin-2-yl}-(1-methyl-piperidin-4-yl)-methanone (130642-50-1) → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 2 steps 1: CF3SO3H / Heating 2: Et3N / toluene / Heating View Scheme

1-Chloro-3-chloromethyl-benzene (620-20-2) → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 5 steps 1: 1.) n-BuLi / 1.) THF, -40 deg C 2: POCl3 / Heating 3: 2.) aq. HCl / 1.) THF, reflux 4: CF3SO3H / Heating 5: Et3N / toluene / Heating View Scheme

chloroformic acid ethyl ester (541-41-3) + N-ethyl-N,N-diisopropylamine (7087-68-5) + N-methyldesloratadine (38092-89-6) → loratadine (79794-75-5)

Conditions	Yield
In toluene; acetonitrile	42.4 g (HPLC purity 97.4%)
In toluene; acetonitrile	42.4 g (HPLC purity 97.4%)

chloroformic acid ethyl ester (541-41-3) + pyrographite (7440-44-0) + N-methyldesloratadine (38092-89-6) → loratadine (79794-75-5)

Conditions	Yield
In toluene; acetonitrile

8-chloro-5,6-dihydro-11H-Benzo[5,6]cyclohepta[1,2-b]pyridin-11-one (31251-41-9) → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 3 steps 1: tetrahydrofuran / Reflux 2: sulfuric acid / 4.5 h / 20 °C 3: triethylamine / toluene / 3 h / Reflux View Scheme

8-chloro-6,11-dihydro-11-(1-methyl-4-piperidinyl)-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ol (38089-93-9) → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 2 steps 1: sulfuric acid / 4.5 h / 20 °C 2: triethylamine / toluene / 3 h / Reflux View Scheme

descarboethoxyloratadine (100643-71-8) + diethyl dicarbonate (1609-47-8) → loratadine (79794-75-5)

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In dichloromethane for 2h;

4-chloro-1-methylpiperidine (5570-77-4) → loratadine (79794-75-5)

Conditions	Yield
Multi-step reaction with 3 steps 1.1: magnesium; iodine / tetrahydrofuran; ethylene dibromide / 1 h / 75 °C / Inert atmosphere 1.2: 1 h / 40 - 50 °C / Inert atmosphere 1.3: 1 h / 20 °C / pH < 2 / Inert atmosphere 2.1: boric acid; sulfuric acid / chlorobenzene / 30 h / 80 - 90 °C 3.1: triethylamine / toluene / 2 h / 80 - 85 °C View Scheme

loratadine (79794-75-5) → descarboethoxyloratadine (100643-71-8)

Conditions	Yield
In ethanol; water Reflux; Inert atmosphere; Alkaline conditions;	98.5%
With C22H40N4(2+)*2BF4(1-) In toluene at 80℃; for 0.666667h;	98.5%
With sodium hydroxide In ethanol; water at 100 - 105℃; for 5h; Concentration; Solvent; Time; Temperature; Autoclave; Inert atmosphere; Large scale;	96%

4-(aminomethyl)pyridine (3731-53-1) + loratadine (79794-75-5) → ethyl 4-(8-((pyridin-4-ylmethyl)amino)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions	Yield
With C47H70BrO4PPdSi; sodium t-butanolate In tetrahydrofuran at 20℃; for 1h; Schlenk technique; Inert atmosphere; Sealed tube;	98%

loratadine (79794-75-5) + potassium vinyltrifluoroborate → ethyl 4-(8-vinyl-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions	Yield
With dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane; palladium diacetate; potassium carbonate In 1,4-dioxane; water at 90℃; for 2h; Schlenk technique; Inert atmosphere;	91%

bromo(2-ethoxy-2-oxoethyl)zinc (5764-82-9) + loratadine (79794-75-5) → ethyl 4-[13-(2-ethoxy-2-oxoethyl)-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene]piperidine-1-carboxylate

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); N,N,N,N,-tetramethylethylenediamine; C38H62P2 In tetrahydrofuran at 20℃; for 16h; Negishi Coupling; Inert atmosphere;	90%

trifluoromethylsulfonic anhydride (358-23-6) + loratadine (79794-75-5) + triphenylphosphine (603-35-0) → (8-Chloro-11-(1-(ethoxycarbonyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate

Conditions	Yield
Stage #1: trifluoromethylsulfonic anhydride; loratadine at -78℃; Inert atmosphere; Stage #2: triphenylphosphine Inert atmosphere; Cooling; Stage #3: Alkaline conditions; Inert atmosphere; regioselective reaction;	88%
at -78 - 20℃; Alkaline conditions;	88%
Stage #1: trifluoromethylsulfonic anhydride; loratadine In dichloromethane at -78℃; Inert atmosphere; Stage #2: triphenylphosphine In dichloromethane at -78 - 20℃; Inert atmosphere; regioselective reaction;

loratadine (79794-75-5) → ethyl 4-[8-hydroxy-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene]-1-piperidine carboxylate

Conditions	Yield
With dicyclohexyl-(2′,4′,6′-triisopropyl-3,6-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine; boric acid; palladium diacetate; caesium carbonate In 1-methyl-pyrrolidin-2-one at 100℃; for 14h; Schlenk technique; Inert atmosphere;	87%

loratadine (79794-75-5) + isopropyl halide → C25H29ClN2O2

Conditions	Yield
With tris-(trimethylsilyl)silane; [Ir[2-(2,4-difluorophenyl)-5-trifluoromethylpyridine]2(4,4′-di-t-Bu-2,2′-bipyridine)]PF6; oxygen; trifluoroacetic acid In acetone at 20℃; for 24h; Minisci Aromatic Substitution; Irradiation; regioselective reaction;	83%

loratadine (79794-75-5) + bis(pinacol)diborane (73183-34-3) → ethyl 4-(8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydro-11Hbenzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions	Yield
With potassium acetate; palladium diacetate; XPhos In 1,4-dioxane at 80℃; for 10h; Schlenk technique;	83%
With tris-(dibenzylideneacetone)dipalladium(0); potassium acetate; XPhos In 1,4-dioxane at 110℃; for 12h; Inert atmosphere; Sealed tube;	705.4 mg

2-fluoroacetophenone (450-95-3) + loratadine (79794-75-5) → (1-fluoro-2-oxo-2-phenylethyl)claritin

Conditions	Yield
With chloro[(di(1-adamantyl)-N-butylphosphine)-2-(2-aminobiphenyl)]palladium(II); caesium carbonate In toluene at 100℃; for 14h; Schlenk technique; Inert atmosphere;	82%

trifluoromethylsulfonic anhydride (358-23-6) + 5-(diphenylphosphaneyl)-2-(trifluoromethyl)pyridine + loratadine (79794-75-5) → (8-chloro-11-(1-(ethoxycarbonyl)piperidin-4-ylidene)-6,11-dihydro-5Hbenzo[5,6]cyclohepta[1,2-b]pyridin-4-yl)diphenyl(6-(trifluoromethyl)pyridin-3-yl)phosphonium trifluoromethanesulfonate

Conditions	Yield
Stage #1: trifluoromethylsulfonic anhydride; 5-(diphenylphosphaneyl)-2-(trifluoromethyl)pyridine; loratadine In dichloromethane at -50℃; for 1h; Inert atmosphere; Stage #2: With 1,8-diazabicyclo[5.4.0]undec-7-ene In dichloromethane at -78 - 20℃; for 0.333333 - 0.5h; Inert atmosphere;	81%

1,3-DIOXOLANE (646-06-0) + loratadine (79794-75-5) → ethyl 4-(8-formyl-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate + ethyl 4-(8-(1,3-dioxolan-4-yl)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions

Yield

Stage #1: 1,3-DIOXOLANE; loratadine With potassium phosphate; (1,2-dimethoxyethane)dichloronickel(II); 4,4'-di-tert-butyl-2,2'-bipyridine for 0.166667h; Glovebox; Stage #2: With [4,4’-bis(1,1-dimethylethyl)-2,2’-bipyridine-N1,N1‘]bis [3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridinyl-N]phenyl-C]iridium(III) hexafluorophosphate at 23℃; for 72h; Sealed tube; Irradiation; Stage #3: With hydrogenchloride In water; acetone at 23℃;

A 78% B n/a

loratadine (79794-75-5) + 2-tri-n-butylstannylpyridine (17997-47-6) → ethyl 4-(8-(pyridin-2-yl)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); cesium fluoride; tri tert-butylphosphoniumtetrafluoroborate In 1,4-dioxane at 100℃; for 12h; Inert atmosphere; Schlenk technique; Sealed tube;	78%

trifluoromethylsulfonic anhydride (358-23-6) + 4-(diphenylphosphaneyl)-2,6-dimethylpyridine + loratadine (79794-75-5) → (8-chloro-11-(1-(ethoxycarbonyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-4-yl)(2,6-dimethylpyridin-4-yl)diphenylphosphonium trifluoromethanesulfonate

Conditions	Yield
Stage #1: trifluoromethylsulfonic anhydride; loratadine In dichloromethane at -78℃; for 0.583333h; Inert atmosphere; Stage #2: 4-(diphenylphosphaneyl)-2,6-dimethylpyridine In dichloromethane at -50℃; for 0.5h; Inert atmosphere; Stage #3: With 1,8-diazabicyclo[5.4.0]undec-7-ene In dichloromethane at -78 - 20℃; Inert atmosphere;	78%

1,1,1-trifluoro-2-chloroethane (75-88-7) + loratadine (79794-75-5) → ethyl 4-(8-(2,2,2-trifluoroethyl)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions	Yield
With 4,4'-di-tert-butyl-2,2'-bipyridine; magnesium chloride; nickel dibromide; zinc In N,N-dimethyl acetamide at 80℃; for 12h; Inert atmosphere; Schlenk technique;	78%

2-(allylsulfonyl)-5-(trifluoromethyl)pyridine + loratadine (79794-75-5) → ethyl 4-(8-(5-(trifluoromethyl)pyridin-2-yl)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions	Yield
With di-tert-butyl(methyl)phosphonium tetrafluoroborate salt; palladium diacetate; caesium carbonate In N,N-dimethyl-formamide at 130℃; for 18h; Inert atmosphere;	77%

loratadine (79794-75-5) → 4-(8-Chloro-7-nitro-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-piperidine-1-carboxylic acid ethyl ester + 4-(8-Chloro-9-nitro-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-piperidine-1-carboxylic acid ethyl ester

Conditions	Yield
With sulfuric acid; potassium nitrate at -5℃; for 16h;	A 12% B 76%

carbon dioxide (124-38-9) + loratadine (79794-75-5) → 8-cyano-11-(1-ethoxycarbonyl-4-piperidylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (143540-41-4)

Conditions	Yield
With nickel(II) acetylacetonate; potassium fluoride; phenylsilane; ammonia; zinc; bis(2-diphenylphosphinoethyl)phenylphosphine In 1-methyl-pyrrolidin-2-one at 90 - 140℃; under 760.051 Torr; for 20h; Sealed tube;	72%

1-fluoro-2-iodoethane (762-51-6) + loratadine (79794-75-5) → C24H27FN2O2

Conditions	Yield
With manganese; 4,4'-Dimethoxy-2,2'-bipyridin; magnesium chloride; nickel dibromide In 1-methyl-pyrrolidin-2-one at 80℃; for 24h; Schlenk technique; Inert atmosphere; Sealed tube;	70%
With manganese; 4,4'-Dimethoxy-2,2'-bipyridin; magnesium chloride; nickel dibromide In 1-methyl-pyrrolidin-2-one at 80℃; for 24h; Inert atmosphere; Sealed tube;	70%

loratadine (79794-75-5) → ethyl 4-(5,6-dihydro-11H-benzo[5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate (79779-58-1) + methyl 4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions	Yield
With tert-Amyl alcohol; tetramethyl ammoniumhydroxide; 2-(2-ethylhexyl)-6,8,11-tris(4-methoxyphenyl)-1H-peryleno[1,12-efg]isoindole-1,3(2H)-dione In methanol at 20℃; for 48h; Birch Reduction; Sealed tube; Irradiation;	A 65% B 26%

N,N-dimethyl acetamide (127-19-5) + loratadine (79794-75-5) → C26H31N3O3

Conditions	Yield
With 2,6-dimethylpyridine; [2,2]bipyridinyl; nickel(II) bromide dimethoxyethane at 30℃; for 48h; Inert atmosphere; Irradiation; regioselective reaction;	63%

potassium hydrogenfluoride (1279123-63-5) + loratadine (79794-75-5) + bis(pinacol)diborane (73183-34-3) → ethyl 4-(8-(trifluoro-λ4-boraneyl)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate potassium salt

Conditions	Yield
Stage #1: loratadine; bis(pinacol)diborane With 10H-phenothiazine; caesium carbonate In acetonitrile at 45℃; for 72h; Irradiation; Sealed tube; Inert atmosphere; Stage #2: With hydrogenchloride; dihydroxy-methyl-borane In water; acetone Stage #3: potassium hydrogenfluoride Further stages;	62%

loratadine (79794-75-5) + tert-butyl halide → C26H31ClN2O2

Conditions	Yield
With tris-(trimethylsilyl)silane; [Ir[2-(2,4-difluorophenyl)-5-trifluoromethylpyridine]2(4,4′-di-t-Bu-2,2′-bipyridine)]PF6; oxygen; trifluoroacetic acid In acetone at 20℃; for 24h; Minisci Aromatic Substitution; Irradiation; regioselective reaction;	61%

loratadine (79794-75-5) + S-methyl-S-phenylsulfoximine (4381-25-3) → ethyl 4-(8-((methyl(oxo)(phenyl)-λ6-sulfaneylidene)amino)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions	Yield
With nickel(II) bromide dimethoxyethane; 4,4'-Dimethoxy-2,2'-bipyridin; tetrabutylammomium bromide; 1,8-diazabicyclo[5.4.0]undec-7-ene In N,N-dimethyl acetamide at 20℃; for 8h; Inert atmosphere; Sealed tube; Electrochemical reaction;	60%

4-chlorotetrahydro-2H-pyran (1768-64-5) + loratadine (79794-75-5) → ethyl 4-(8-(tetrahydro-2H-pyran-4-yl)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions	Yield
With 2,2'-biimidazole; (1,2-dimethoxyethane)dichloronickel(II); (4,4'-di-tert-butyl-2,2'-dipyridyl)-bis-(2-phenylpyridine(-1H))-iridium(III) hexafluorophosphate; N,N,N′,N′-tetramethyl-N″-tert-butylguanidine; N-(adamantan-1-yl)-1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-amine In tert-Amyl alcohol; N,N-dimethyl acetamide at 55℃; for 18h; Inert atmosphere; Irradiation;	58%

loratadine (79794-75-5) + trimethyl orthoformate (149-73-5) → ethyl 4-(8-methyl-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate (130642-61-4)

Conditions	Yield
Stage #1: loratadine; trimethyl orthoformate With potassium phosphate; [nickel(II)dichloride(dimethoxyethane)]; [4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine-N1,N1]bis-{3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridinyl-N]phenyl-C}iridium(III) hexafluorophosphate; 4,4'-di-tert-butyl-2,2'-bipyridine at 20℃; for 72h; Irradiation; Sealed tube; Stage #2: With palladium on activated charcoal; hydrogen In methanol at 20℃; under 1551.49 Torr; for 10h;	57%
With potassium phosphate; [nickel(II)dichloride(dimethoxyethane)]; [4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine-N1,N1]bis-{3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridinyl-N]phenyl-C}iridium(III) hexafluorophosphate; 4,4'-di-tert-butyl-2,2'-bipyridine at 20℃; for 72h; Irradiation; Sealed tube;	51%

loratadine (79794-75-5) + S-(4-methoxyphenyl)-S-methylsulfoximine (77970-95-7) → ethyl 4-(8-(((4-methoxyphenyl)(methyl)(oxo)-λ6-sulfaneylidene)amino)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions	Yield
With nickel(II) bromide dimethoxyethane; 4,4'-Dimethoxy-2,2'-bipyridin; tetrabutylammomium bromide; 1,8-diazabicyclo[5.4.0]undec-7-ene In N,N-dimethyl acetamide at 20℃; for 8h; Inert atmosphere; Sealed tube; Electrochemical reaction;	57%

2-(2-methylphenyl)pyridine (10273-89-9) + loratadine (79794-75-5) → C34H33N3O2

Conditions	Yield
With C17H24N5Ru(1+)*F6P(1-); potassium acetate; potassium carbonate In 1-methyl-pyrrolidin-2-one at 50℃; for 72h; Inert atmosphere;	56%
With C17H24N5Ru(1+)*F6P(1-); potassium acetate; potassium carbonate In 1-methyl-pyrrolidin-2-one at 50℃; for 72h; Inert atmosphere; Glovebox;	56%

2,3-dimethyl-2,3-butane diol (76-09-5) + tetrahydroxydiboron (13675-18-8) + loratadine (79794-75-5) → ethyl 4-(8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydro-11Hbenzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate

Conditions	Yield
Stage #1: tetrahydroxydiboron; loratadine With chloro(2-dicyclohexylphosphino-2’,4’,6’-triisopropyl-1,1‘-biphenyl)[2-(2’-amino-1,1‘-biphenyl’)]palladium(II); potassium acetate; XPhos In ethanol at 80℃; Stage #2: 2,3-dimethyl-2,3-butane diol In dichloromethane at 20℃; for 16h;	52%

Upstream product

• 541-41-3 chloroformic acid ethyl ester 
• 38092-89-6 N-methyldesloratadine 
• 20970-75-6 2-cyano-3-methylpyridine 
• 165740-12-5 ethyl 4-(3-bromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate 
• 5570-77-4 4-chloro-1-methylpiperidine 
• 216870-24-5 diethyl N-ethoxycarbonylpiperidine-4-phosphonate 
• 100643-71-8 descarboethoxyloratadine 
• 1609-47-8 diethyl dicarbonate 
• 38089-93-9 8-chloro-6,11-dihydro-11-(1-methyl-4-piperidinyl)-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ol 
• 31251-41-9 8-chloro-5,6-dihydro-11H-Benzo[5,6]cyclohepta[1,2-b]pyridin-11-one 
• 7440-44-0 pyrographite 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 620-20-2 1-Chloro-3-chloromethyl-benzene 
• 130642-50-1 {3-[2-(3-Chloro-phenyl)-ethyl]-pyridin-2-yl}-(1-methyl-piperidin-4-yl)-methanone 

Downstream Products

• 100643-71-8 descarboethoxyloratadine 
• 1373612-32-8 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-N-cyclohexyl-1-piperidinecarbothioamide 
• 1373612-33-9 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-N-phenyl-1-piperidinecarbothioamide 
• 1373612-34-0 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-N-(2-methylphenyl)-1-piperidinecarbothioamide 
• 183741-33-5 [(R)-2-[4-(8-Chloro-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-piperidin-1-yl]-1-(4-methoxy-benzylsulfanylmethyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Preparation method of loratadine

The invention provides a preparation method of loratadine. The method comprises the following steps: taking 2-cyano-3-methylpyridine as a raw material, and carrying out Ritter reaction, m-chlorobenzylchloride condensation, POCl3 deprotection group, Grignard reaction, cyclization and ethyl chloroformate substitution to obtain 4(8-chlorine-5, 6-dihydro-11H-benzo-[5, 6]cycloheptano[1, 2-b]pyridine-11-subunit)-1-piperidine carboxylic acid ethyl ester. According to the invention, a post-treatment process is innovated, and a new cyclization system is adopted to catalyze the reaction, so that the use of high-cost and high-toxicity strong acid is avoided, and a milder and more economical synthesis method is provided for industrial production.

NEW PROCESS FOR PREPARING LORATADINE FROM A KETONE INTERMEDIATE

This application is directed to a last step synthetic process for making loratadine from ketone intermediate.

Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents

Thiourea derivatives (6a-e) were developed and screened for antitumor and anti-inflammatory activity. Most of the compounds exhibited growth inhibitory effects comparable to 5-fluorouracil in vitro against mammary (MCF-7 and MDA-MB 231) as well as colon (HT-29) carcinoma cells. They also showed stronger anti-inflammatory activity than ibuprofen in vivo in the xylene-induced ear swelling assay in mice.